Purple Biotech Ltd. · TASE:PPBT
Purple Biotech — Kitov Pharma — Investor Presentation (April 2019)
19 slides from Purple Biotech's investor presentation, Apr 15, 2019
Slide 1: CM-24: A Novel Immune Checkpoint Inhibitor
CM-24: A Novel Immune Checkpoint Inhibitor Investors Call - April 2019
Slide 2: Forward-Looking Statements and Kitov's Safe Harbor Statement
Forward-Looking Statements and Kitov’s Safe Harbor Statement Certain statements in this presentation are forwaroking statements within the meaning of the safe harbor provisions ofthe Private Secures Litigation Reform Act of 1985 and other appleble secures laws. Forward-looking statements can be deni
Slide 3: CM-24 Opportunity
CM-24 Opportunity * Monoclonal Ab targeting CEACAM1, a novel immune checkpoint with high potential to treat multiple oncology indications * CM-24 was well tolerated in a Phase 1 study in doses up to 10mg/kg * Only clinical stage therapeutic candidate currently targeting CEACAM1, * Plan to develop in
Slide 4: CEACAM1 is a Member of the Human CEA Family
CEACAM1 is a Member of the Human CEA Family (Carcinoembryonic Antigen Cell Adhesion Molecule) Aernatve CDSie,8GP —CDstdand_ COM COsteand —CDssend COM Cue and timer Seca CGN ca Rew ay Tasue | Epthinel, Gronloctes_Granulocytes__pithelal__—_—Ephlatcls phates Garuloets xprsson — sdotisl ces eas hd auloy
Slide 5: CEACAM1 is Expressed in Both Tumor and Tumor-infiltrating Immune Cells
kitov Dre . . ?y@ Po G CEACAM1 is Expressed in Both Tumor and Tumor- PP 9s infiltrating Immune Cells baat oe Melanoma (70%) Bladder (96%) Lung (50%) Gastric (74%) Bladder carcinoma Colon (92%) Pancreas (94%) Prostate (63%) Pancreas ——| CEACAM1 staining with MGR1 (murine version of CM-24) on various
Slide 6: CM-24 - Mechanism of Action
CM-24 - Mechanism of Action Conceptually, analogous to PD-1/PDL-1 M24 blocks CEACAM1/1 and CEACAM1/5 interactions evoking anti tumor immune response (Tumor) CEACAM1/5 — (T-cell) CEACAM interaction prevents killing of tumor cells through: a) Inhibition of the immune activity yee D of TiLs, b) lowerin
Slide 7: CM-24 - Mechanism of Action (cont.)
CM-24 - Mechanism of Action (cont.) By blocking CEACAM-1 heterodimerization with TIM-3, immune exhaustion of T-cells is abrogated, allowing cooperative tumor inhibition a mouse IgG SaPoLtma mouse IgSt Emm Therapeutic protocol Paes zet Eee EEN Prodi Preventative protocol © CEACAM mAb _ el ee 5s ee 4
Slide 8: Sustained Inhibition Of Lung Tumor Growth Following Treatment with CM-24 + TIL
Sustained Inhibition Of Lung Tumor Growth Following Treatment with CM-24 + TIL 100 _* > Bw Ti+ gs e ar) a ge TW +cM-24] 2 5 H 3 to 2 oo nave : root B 2 I zo metas mcm re + Xenograft, lung lesion melanoma model + Tumor burden was monitored 26 days post last CM-24 treatment
Slide 9: Synergistic Anti-Cancer Effect Following Treatment with CM-24 + Anti PD-1
Synergistic Anti-Cancer Effect Following Treatment with CM-24 + Anti PD-1 site i g608 yoo 40000) medium _ eee ram tii ada asp) najgea 7 eave eat 0.05 pgimt | Ot alm! = O.2ugImE 0.4 Haid Combination index (Cl) = 0.15 ©) | De Cl=p),* Dy ~<1> synergism kitov
Slide 10: Phase 1 CM-24 Trial Data
Phase 1 CM-24 Trial Data wT Dose tpt. + Opentabel, multi-dose escalation 27 Patients: study to assess the safety and Colorectal 11 tolerability of CM-24 as a monotherapy and in combination Melanoma 7 with pembrolizumab (Keytruda®)* me o3meke | 3 | Ovarian 4 == En * Conducted by Merck in 4 centers Ga
Slide 11: Phase 1 CM-24 Trial Data
Y é Phase 1 CM-24 Trial Data Pee, Saturation Was Not Reached With Doses Up to 10mg/Kg “e 0.1 mg/kg 0.3 mg/kg mg/kg 3 mg/kg 10 me/kg
Slide 12: Moving Forward With CM-24
Moving Forward With CM-24 * (CM-24 has a good safety and tolerability profile + CM-24 + aPD-1 antibody combination demonstrated synergistic anti-cancer effect — Opdivo® is a good candidate for a combination therapy replicating the Opdivo®/Yervoy® success — Dosing level based on PK - start at mg/kg a
Slide 13: Upcoming Milestones (Post CM-24 Transaction)
Upcoming Milestones (Post CM-24 Transaction) CM-24 - Shareholders approval of the transaction 2:19 NT-219 - Complete pre-clinical development plan H1:19 CM-24 - Closing of the transaction 03:19 NT-219 - Submit IND application to FDA H2:19 NT-219 - Initiation of a clinical study H2:19 Consensi™ - Com
Slide 14: Company Overview (Post CM-24 Transaction)
Company Overview (Post CM-24 Transaction) Kitov Pharma is advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression DIVERSE PIPELINE gy ADDRESSING LARGE MARKETS. + NT-219 - small molecule designed to overco
Slide 15: Company Headquarters, US Medical Research Office, Contact Us
Company Headquarters US Medical Research Office Contact Us One Azrieli Center 1615 Suter's Lane NW Email: IR@kitovpharm Round Tower, Floor 19 Washington DC 20007 132 Begin Road Tel. 972 39333121 Tel Aviv 670110 Israel
Slide 16: EXHIBITS
EXHIBITS —_ 16
Slide 17: Human CEACAM1 is a Modulator of T cell Function
Human CEACAM1 is a Modulator of T cell Function * Human CEACAM1 is a modulator of T-cell function + CEACAM1 expression up-regulated on * Activated T and NK cells * Various cancer cells + CEACAM1(tumor) and CEACAMI (T-cell) interaction prevents killing of tumor cell * CEACAM-1 inhibition also noted t
Slide 18: Saturation Was Not Reached With Doses Up to 10mg/Kg (cont.)
Saturation Was Not Reached With Doses Up to 10mg/Kg (cont.) 2-compartment PK model including TMDD was performed by Merck. Model was simulated to characterize TMDD saturation: Simulated TMDD saturation at Ctrough with Q2W regimen Predictions with Q3W regimen (not clinically tested) 100 = “ vt i ehh o
Slide 19: Inhibition of Melanoma Growth Following CM-24 and CM24 + TIL Treatment
Inhibition of Melanoma Growth Following CM-24 nay . oa and CM24 + TIL Treatment a CM-24 activity is demonstrated as single agent and in combination with TILs “50 Bn 10me/ke 400 -S-cw2e tome/ke 350 TIL+ 6 10mg 300 Ont C24 10me/ks ‘Tumor Volume (mm*3 #SE) 30 40 50 ca 70 80 Time (D) 10